Hangzhou Tigermed Consulting Co., Ltd
HNGZY - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.72B
Close$
$3.51
21.1% downside
Current Fair Value
21.1% downsideOvervalued by 21.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $3.72 Billion |
|---|---|
| Enterprise Value | $4.02 Billion |
| Annual dividend | $0.01 |
| Dividend yield | 0.25% |
| Earnings per Share | $1.04 |
| Beta | 0.41 |
| Outstanding Shares | 836,354,301 |
Return
| Return on Equity | 0.48% |
|---|---|
| Return on Assets | 0.33% |
| Return on Invested Capital | 6.78% |
Valuation & Multiples
| P/E Ratio | -76.42 |
|---|---|
| PEG | 24.53 |
| Price to Sales | 0.56 |
| Price to Book Ratio | 0.16 |
| Enterprise Value to Revenue | 0.55 |
| Enterprise Value to EBIT | 2.35 |
| Enterprise Value to Net Income | 43 |
| Total Debt to Enterprise | 0.58 |
| Debt to Equity | 0.12 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Hangzhou Tigermed Consulting Co., Ltd
11,984 employees
CEO: Xiao Chun Cao
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. The company offers clinical trial operation services, such as ...